PPIDT00275
Drug Information
| Name | Lixisenatide |
|---|---|
| Sequence | HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK |
| DrugBank_ID | DB09265 |
| Type | biotech |
| Indication | Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus.[L48400] It is also available in combination with [insulin glargine] for the same indication.[L48405] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
100 ug/1mL
|
| Injection, solution; kit | Subcutaneous |
|
| Kit; solution | Subcutaneous |
|
| Solution | Subcutaneous |
10 mcg / act
|
| Solution | Subcutaneous |
20 mcg / act
|
| Injection | — |
0.05 MG/ML
|
| Injection | — |
0.1 MG/ML
|
| Injection, solution | Parenteral; Subcutaneous |
10 MICROGRAMMI
|
| Injection, solution | Parenteral; Subcutaneous |
20 MICROGRAMMI
|
| Injection, solution | Subcutaneous |
10 ug
|
| Injection, solution | Subcutaneous |
20 ug
|
| Solution | Parenteral |
0.050 mg
|
| Solution | Subcutaneous |
0.15 mg/3ml
|
| Solution | Subcutaneous |
0.3 mg/3ml
|
| Injection, solution | — |
10 mcg
|
| Injection, solution | Subcutaneous |
10 mcg/0.2ml
|
| Injection, solution | — |
20 mcg
|
| Injection, solution | Subcutaneous |
20 mcg/0.2ml
|
| Injection, solution | Subcutaneous |
50 mcg/mL
|
| Injection, solution | Subcutaneous |
0.05 mg/mL
|
| Injection, solution | Subcutaneous |
100 mcg/mL
|
| Solution | Subcutaneous |
0.05 mg
|
| Solution | Subcutaneous |
0.1 mg
|
| Solution | Subcutaneous |
|
| Injection, solution | Subcutaneous |
|
| Injection, solution | Subcutaneous |
100 units/ml
|
| — | Subcutaneous |
|
| Injection, solution | Cutaneous; Parenteral |
|
| Injection, solution | — |
|